Dexcom (DXCM) has been in the public eyes for various reasons. Key growth was noticeable in its
Glucose Monitoring Technology, making it a top pick for long-term investors. After beating earnings forecasts,
Mizuho raised Dexcom’s price target to $90 from $78. The company shares important outcomes for people with type 2 Diabetes and shows impressive product roadmap at ATTD 2026, eluding increased potential for higher future growth. Notably, the
15-Day CGM and possible reimbursement wins are highlighted as future catalysts. While some investors such as Capital Research Global and Alamar Capital Management cut their holdings, others like
Mackenzie Financial Corp increased theirs citing potential growth. Dexcom’s addition of Google’s tech expert, Rick Osterloh, to its board could signal a restructuring of its innovation strategy. With its ongoing focus on glucose sensor leadership and several upgrades citing recovery and G7 margin potential, the company's financials look promising. However, the stock has seen a few dips recently prompting Barclays to downgrade the stock citing intensifying competition. Despite the swings, analysts regard DexCom as a prime example of growth at a reasonable price.
Q4 preliminary figures and 2026 Guidance predict a positive future for Dexcom.
Dexcom DXCM News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sat, 14 Mar 2026 04:07:11 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 6
